Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

Phase 2 Completed 295 enrolled Sagent Pharmaceuticals Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled study of camostat mesilate in ambulatory patients with confirmed COVID-19 with at least one risk factor for severe illness.

Timeline

Start: 2020-11-09
Primary completion: 2021-03-31
Completion: 2021-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camostat	Small molecule	200 mg	Oral

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

Summary

Timeline

Drugs

Indications